UK markets closed
  • FTSE 100

    -66.25 (-0.97%)
  • FTSE 250

    -160.16 (-0.77%)
  • AIM

    -10.50 (-0.89%)

    -0.0014 (-0.12%)

    -0.0108 (-0.79%)

    +581.26 (+2.26%)
  • CMC Crypto 200

    -33.21 (-4.52%)
  • S&P 500

    -27.29 (-0.72%)
  • DOW

    -177.26 (-0.57%)

    -1.53 (-2.86%)

    -23.70 (-1.28%)
  • NIKKEI 225

    -179.08 (-0.62%)

    +77.00 (+0.27%)
  • DAX

    -200.97 (-1.44%)
  • CAC 40

    -69.45 (-1.22%)

Global Human Insulin Market, By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025

·6-min read

Global Human Insulin Market, By Indication (Type I Diabetes, Type II Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Pre-Mixed, Inhaled, Ultra-Long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By Region, Forecast & Opportunities, 2025

New York, Jan. 04, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Global Human Insulin Market, By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025" -

Global human insulin market was valued at USD 26.91 Billion in 2019 is expected to grow at a steady CAGR of 8.01% during the forecast period. Growing geriatric population, increasing diabetic patients, rising prevalence of obesity, and increasing demand for human insulin analogs are contributing to the surging demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness, reimbursement prices and strict regulatory requirements for approval of insulin can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin.

The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products, and region.Based on indication, market can be bifurcated into type I diabetes and type II diabetes.

Type I diabetes is likely to hold the largest market share until 2025 as, human insulin is the most important treatment method for the people suffering from type I diabetes. Based on brand, Lantus segment held the dominant market which is one of the major selling products of Sanofi S.A. As of 2019, subcutaneous segment was the leading segment on the basis of route of administration. This is the most common and preferred route of administration as the insulin is absorbed more quickly. Based on regional analysis, North America dominated the human insulin market in 2019 due to large pool of population suffering from diabetes and presence of leading companies in countries like US and Canada.

Leading players in the global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk A/S, Torrent Pharmaceuticals, Inc., Eli Lilly and Company, A-S Medication Solutions, RemedyRepack Inc., Sedico Co., Pharmaceutical Company, Sanofi S.A., Gan & Lee Pharmaceuticals, BioGenomics Ltd., Pfizer Inc., PerkinElmer, Merck & Co., Inc, Biocon Limited, Wockhardt Ltd., Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., among others.

Years considered for this report:

Historical Years: 2015-2018
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2021–2025

Objective of the Study:

• To analyze and forecast the market size of global human insulin market.
• To classify and forecast global human insulin market based on indication, brand, route of administration, type, onset type, products and region.
• To identify drivers and challenges for global human insulin market.
• To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global human insulin market.
• To conduct pricing analysis for global human insulin market.
• To identify and analyze the profile of leading players operating in global human insulin market.
The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of hospitals/clinics across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the hospitals/clinics which could not be identified due to the limitations of secondary research. The analyst examined the hospitals/clinics and presence of all major players across the globe.
The analyst calculated the market size of global human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

• Hospitals/clinics, research institutes and other stakeholders
• Government bodies such as regulating authorities and policy makers
• Organizations, forums and alliances related to human insulin
• Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals/clinics, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
• Market, By Indication:
o Type I Diabetes
o Type II Diabetes
• Market, By Brand:
o Lantus
o Humulin R
o Novolin R
o Humulin N
o Exubera
o Afrezza
o Novolin N
• Market, By Route of Administration:
o Subcutaneous
o Nasal
o Intravenous
o Transdermal
o Oral
o Others
• Market, By Type:
o Basal
o Bolus
o Pre-mixed
o Biosimilar
o Traditional
• Market, By Onset Time:
o Rapid acting
o Short-acting
o Intermediate acting
o Long acting
o Ultra-long acting
o Pre-mixed
o Inhaled
• Market, By Products:
o Insulin Pens
o Insulin Pumps
o Infusion System
o Injection
• Market, By Region:
o North America
United States
o Europe
United Kingdom
o Asia-Pacific
South Korea
o South America
o Middle east & Africa
Saudi Arabia
South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global human insulin market.

Available Customizations:

With the given market data, we offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001